On June 27, the 2023 China Medical and Health Industry Symbiosis Conference was grandly held in Huzhou, Zhejiang Province. The event brought together representatives from government departments, industry associations, chain pharmacies, pharmaceutical companies, hospitals and retail terminals, innovation and technology platforms, CXO enterprises, pharmaceutical industry parks, and media. During the conference, the 2022 Top 100 Chinese Pharmaceutical Enterprises List was released, with JumpCan Pharmaceutical securing the 7th position in the "TOP 100 Chinese TCM Enterprises" category.
JumpCan Pharmaceutical's Certificate of Honor
Centered around the theme of "Winning with Quality in a New Cycle", the conference explored how enterprises can enhance the quality of their products and services. The selection criteria for the ranking focused on the innovation drive and professional promotion capabilities of pharmaceutical industrial enterprises, evaluating them against comprehensive R&D investment metrics and clinical demand-oriented end-user data. This accolade recognizes JumpCan Pharmaceutical's achievements in the innovative development of traditional Chinese medicine (TCM), highlighting the company's strengths and brand value in high-quality TCM development.
Scene at the Conference
Honoring the essence while preserving authenticity and fostering innovation, JumpCan Pharmaceutical adheres to the R&D philosophy of "Leading the Frontier, Innovating Fine Products". Guided by clinical needs, the company leverages advantages of research platforms such as the Postdoctoral Research Workstation and the Jiangsu Provincial Key Laboratory of Pediatric Chinese Medicine and Specialized Formulations to accelerate the scaling, modernization, and industrialization of TCM. In 2022, the company's R&D investment exceeded 500 million RMB, accounting for 6.26% of its revenue, and multiple measures have been implemented to continuously stimulate innovation-driven development.
Quality first, pursuing excellence. The company insists on controlling the quality of medicinal materials at the source, establishing genuine TCM planting bases and building a quality assurance system from the field to the workshop. It enhances intelligent manufacturing of TCM by introducing internationally advanced production lines and establishing a full-process digital operating system from production to storage, boasting strong production and supply capabilities for multiple dosage forms. The company also strengthens clinical research on products, enriches evidence-based medical data, supports academic exchanges in TCM clinical application, and promotes rational drug use in clinical practice.
The company has developed and launched several major TCM products leading in their respective segments—such as Pudilan Xiaoyan Oral Liquid, Xiao'er Chiqiao Qingre Granules (Tonpei), and Jianwei Xiaoshi Oral Liquid—which are highly trusted and well-regarded by doctors, pharmacists, and patients. JumpCan Pharmaceutical is deeply engaged in the secondary development of major TCM products and the R&D of improved innovative TCM drugs, accelerating the transformation of scientific and technological achievements and contributing to the innovative development of the TCM industry. The clinical research on Pudilan Xiaoyan Oral Liquid, a demonstration product under the National Key R&D Program, has passed review, and the application for production of Xiao'er Chiqiao Qingre Syrup—the first improved innovative TCM drug in China—is under review.
Moving forward, JumpCan Pharmaceutical will continue to inherit and develop TCM, driven by innovation, embracing transformation, and remain committed to high-quality R&D oriented toward meeting differentiated clinical medication needs. The company will strengthen the building of its TCM brand, provide high-quality TCM products, and strive to become a leading, comprehensive pharmaceutical group trusted by patients in China.